June 17, 2025

---

John E Milad, CEO, ERS Genomics: One Year On - The Future of CRISPR is Now

May 16, 2025

---

CVC successfully appeals prior CRISPR U.S. patent decision

April 22, 2025

---

AI + CRISPR: Powering the 21st century’s biological revolution

March 28, 2025

---

ERS Genomics and Jumpcode Genomics sign CRISPR/Cas9 license agreement

February 26, 2025

---

European Patent Office grants CVC portfolio key CRISPR patent

January 29, 2025

---

ERS Genomics - Annual letter from The CEO

January 17, 2025

---

ERS Genomics launches ‘Express License’ platform to democratise access to CRISPR/Cas9

May 14, 2024

---

ERS Genomics appoints John E Milad as Chief Executive Officer

March 26, 2024

---

Key Charpentier/Doudna CRISPR patent upheld by China National Intellectual Property Administration

December 15, 2023

---

Key Charpentier/Doudna CRISPR patent upheld by Japanese Patent Office · Patent JP6692856 upheld for second time in response to invalidation challenge

June 1, 2023

---

ERS Genomics and Applied Biological Materials enter into CRISPR/Cas9 licensing agreement

January 5, 2023

---

Foundational CRISPR/Cas9 gene editing patent granted to CVC in Canada

December 8, 2022

---

Crown Bioscience and ERS Genomics announce global CRISPR/CAS9 licensing agreement for genome editing patents

February 23, 2021

---

ERS Genomics and G+FLAS Life Sciences sign CRISPR/Cas9 license agreement

June 27, 2017

---

DuPont Pioneer secures exclusive rights to ERS Genomics’ CRISPR-Cas patent portfolio for agriculture

May 17, 2016

---

Bayer and ERS Genomics announce licensing agreement for Genome Editing Patents - The agreement offers broad access to research applications via promising CRISPR-Cas9 gene editing technology